Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1641-1645

  Mangia, Anita ^a   Tommasi, Stefania ^a   Bruno, Michele ^a   Malfettone, Andrea ^a   D'Amico, Cosimo ^a   Zito, Francesco Alfredo ^a   Paradiso, Angelo ^a   Simone, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

BRCA genes risk mutation; Extratumoral breast lesions; UDH; Vascular peritumoral invasion

Indexed keywords

ADULT; ARTICLE; ATROPHY; BREAST CANCER; BREAST LESION; CANCER GRADING; FAMILIAL CANCER; FEMALE; FIBROADENOMA; FIBROSIS; GENE MUTATION; HISTOLOGY; HUMAN; HYPERPLASIA; MAJOR CLINICAL STUDY; PAPILLOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; MIDDLE AGED; MUTATION; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 77951758855     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000806     Document Type: Article

References (33)

1. Ahmed M and Rahman M: ATM and breast cancer susceptibility. Oncogene 25: 5906-5911, 2006.
2. Antoniou AC and Easton DF: Models of genetic susceptibility to breast cancer. Oncogene 25: 5898-5905, 2006.
3. Easton DF, Pooley KA, Dunning AM, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093, 2007.
4. Lakhani SR, Gusterson BA, Jacquemier J, et al: The pathology of familial breast cancer: pathological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6: 782-789, 2000.
5. Palacios J, Honrado E, Osorio A, et al: Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9: 3606-3614, 2003.
6. Kroiss R, Winkler V, Kalteis K, et al: Prevalence of premalignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group. J Cancer Res Clin Oncol 134: 1113-1121, 2008.
7. Hartmann LC, Sellers TA, Frost MH, et al: Benign breast disease and the risk of breast cancer. N Engl J Med 353: 229-237, 2005.
8. Hoogerbrugge N, Bult P, Bonenkamp JJ, et al: Numerous highrisk epithelial lesions in familial breast cancer. Eur J Cancer 42: 2492-2498, 2006.
9. Aaman TB, Stalsberg H and Thomas DB: Extra-tumoral breast tissue in breast-cancer patients: variations with a family history of breast cancer. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 79: 39-43, 1998.
10. Adem C, Reynolds C, Soderberg CL, et al: Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97: 1-11, 2003.
11. Hoogerbrugge N, Bult P, De Widt-Levert LM, et al: High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21: 41-45, 2003.
12. Bruno M, Tommasi S, Stea B, et al: Awareness of breast cancer genetics and interest in predictive genetic testing: a survey in Southern Italian population. Ann Oncol (Suppl 1): I48-I54, 2004.
13. Tommasi S, Crapolicchio A, Lacalamita R, et al: BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res 578: 395-405, 2005.
14. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20: 1480-1490, 2002.
15. Tavassoli FA and Devilee P: Pathology and genetics of tumors of the breast and female genital organs. In: The World Health Organization Classification of Tumors. Tavassoli FA and Devilee P (eds). IARC Press, Lyon, pp19-23, 2003.
16. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41: 154-161, 2002.
17. Mangia A, Chiriatti A, Tommasi S, et al: BRCA1, ERα expression and molecular BRCA1 alterations in familial breast cancer. Histol Histopathol 24: 69-76, 2009.
18. Paradiso A, Volpe S, Iacobacci A, et al: Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarker (INQAT). Int J Biol Markers 17: 201-214, 2002.
19. Collaborative Group on Hormonal Factors in Breast Cancer: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358: 1389-1399, 2001.
20. Mohammed SN, Smith P, Hodgson SV, et al: Family history and survival in premenopausal breast cancer. Br J Cancer 77: 2252-2256, 1998.
21. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS and Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151: 703-714, 2000.
22. Chang J and Elledge RM: Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 69: 101-113, 2001.
23. Molino A, Giovannini M, Pedersini R, et al: Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br J Cancer 91: 96-98, 2004.
24. Russo A, Herd-Smith A, Gestri D, Bianchi S, Vezzosi V, Rosselli Del Turco M and Cardona G: Does family history influence survival in breast cancer cases? Int J Cancer 99: 427-430, 2002.
25. Eisinger F, Jacquemier J, Charpin C, et al: Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58: 1588-1592, 1998. (Pubitemid 28215075)
26. Krainer M, Silva-Arrieta S, FitzGerald MG, et al: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 15: 1416-1421, 1997.
27. Langston AA, Malone KE, Thompson JD, Daling JR and Ostrander EA: BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 18: 137-142, 1996.
28. Veronesi A, De Giacomi C, Magri MD, et al: Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer 5: 70, 2005
29. Pantel K and Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456, 2004.
30. Mohammed RA, Ellis IO, Lee AH and Martin SG: Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms (Review). Histopathology 55: 1-9, 2009.
31. Worsham MJ, Raju U, Lu M, Kapke A, Cheng J and Wolman SR: Multiplicity of benign breast lesions is a risk factor for progression to breast cancer. Clin Cancer Res 15: 5474-5479, 2007.
32. Webb PM, Byrne C, Schnitt SJ, et al: Family history of breast cancer, age and benign breast disease. Int J Cancer 100: 375-378, 2002.
33. Kauff ND, Brogi E, Scheuer L, et al: Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97: 1601-1608, 2003.